Registry update — unassessed
A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 11, 2023 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The study does not report results; it describes aims and hypotheses only, so no efficacy claim can be assessed.
- LC3 levels in leukocytes are a surrogate marker with unclear relationship to aging outcomes or clinical longevity.
- The hypothesis links metformin to multiple downstream mechanisms (reduced inflammation, muscle preservation, cardiovascular benefits, neuroprotection) but the study only measured one surrogate outcome; it could not establish which, if any, of these mechanisms occurred.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Adult patients with prediabetes
- Primary outcome
- Increased levels of LC3 in leukocytes
- Effect size
- —
- Significance
- Not reported
- Journal
- University of New Mexico
- Published
- Dec 11, 2023
Sources
Primary source
- University of New Mexico ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
A Double-Blind, Placebo-Controlled Trial
This pilot and feasibility study is to investigate the effects of a short course of metformin therapy on a surrogate marker of cellular senescence and autophagy among adult patients with prediabetes
Primary outcome: Increased levels of LC3 in leukocytes
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.